The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bayer

Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY 1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical activity.
 
Jennifer Robinson Diamond
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Casi Pharmaceuticals (Inst); Genentech/Roche (Inst); MedImmune (Inst); Millennium (Inst); OncoMed (Inst); Rexahn Pharmaceuticals (Inst); Scripps Hospital (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Takeda; Takeda
 
Victor Moreno
No Relationships to Disclose
 
Emerson A. Lim
No Relationships to Disclose
 
Raul Cordoba
No Relationships to Disclose
 
Charles Cai
No Relationships to Disclose
 
Stuart James Ince
Employment - Bayer
 
John T. Lettieri
Employment - Bayer
 
Claudia Merz
Employment - Bayer
 
Ray Valencia
Employment - Bayer
 
Valentina Boni
No Relationships to Disclose